Skip to main content
OpenTrials
Completed

NCT Number: NCT01082471

An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours

To compare the incidence and severity of nausea in the study treatment groups, during the 18-hour period starting 6 hours after titration to pain relief; following confirmation of the assumption of non-inferiority between the two groups of pain relief over the 24 hour post-operative period. Pain relief and nausea will be determined by measuring the areas under the curves of pain intensity and nausea verbal rating scale scores.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Teaching Hospital Bulovka, Department of Urology, Prague, Czechia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients undergoing any of the following elective surgical procedures that, in the Investigator's opinion, would have required the use of post-operative patient controlled analgesia for a minimum of 24 hours:
  • Abdominal hysterectomy with the exception of laparoscopic procedures.
  • Bowel / gastrointestinal (GI) surgery
  • Major urological surgery
  • Aged ≥ 18 years
  • American Society of Anesthesiologists (ASA) grades I to III
  • If female, the patient had to be post-menopausal (last menstruation > 1 year previously), or surgically sterile (e.g. full hysterectomy or tubal ligation). If neither of these was the case, she had to use adequate contraception (i.e. hormonal contraceptive, intrauterine device (IUD), or a double barrier method) and to have a negative urine pregnancy test during the 24-hours prior to surgery.
  • Provide written informed consent to participate in the trial prior to surgery.

Exclusion criteria

  • The patient was pregnant or lactating.
  • Had a known sensitivity to morphine or other opiates, or a medical condition such that opiates were contraindicated.
  • Had a known sensitivity to paracetamol, or a medical condition such that paracetamol was contraindicated.
  • Had received any investigational drug within the 90 days prior to the start of the study, or was scheduled to receive one during the study period.
  • Had been involved in any previous M6G study.
  • Had a documented history or current evidence of alcohol or drug abuse within the year prior to screening.
  • Had clinically significant findings on pre-treatment evaluations (e.g. laboratory results, electrocardiograms, medical history, physical examination) that, in the Investigator's opinion, should have excluded them from the study.
  • Had a concurrent disorder that resulted in excessive pain that, in the Investigator's opinion, would have interfered with the pain assessments during the study (e.g.severe rheumatoid arthritis, muscle dystrophy or neuropathic pain).
  • Had a blood clotting disorder or other blood dyscrasias.
  • Had requested the use of epidural or intrathecal anaesthesia techniques.
  • Required the use of a local anaesthetic block and/or infiltration of wound sites.
  • Required the concomitant use of opioids or non-steroidal anti-inflammatory drugs(NSAIDs) during the study due to an existing concurrent condition.
  • Had a history of Left Ventricular Failure or compromised cardiovascular function, defined as New York Heart Association (NYHA) level 3.
  • Had a history of severe renal impairment or a creatinine level > 3 times the upper limit of normal.
  • Was having surgery that would have prevented the use of oral or rectal paracetamol(iv administration of paracetamol was not allowed).
  • Was expected to require prolonged ventilation after surgery.
  • Was opioid tolerant or had a history of chronic opioid use.
  • Had cognitive impairment that would, in the Investigator's opinion, have precluded participation or compliance with protocol defined procedures (i.e. use of PCA).

Treatment and study plan

Morphine 6-glucuronide

Drug

Morphine

Drug

Primary outcomes

  1. Incidence and severity of nausea

    Time frame: The 6-18 hour period after titration to pain relief

    To compare the incidence and severity of nausea in the study treatment groups, during the 18-hour period starting 6 hours after titration to pain relief; following confirmation of the assumption of non-inferiority between the two groups of pain relief over the 24-hour post-operative period. Pain relief and nausea were determined by measuring the areas under the curves of pain intensity and nausea verbal rating scale scores.

Secondary outcomes

  1. Analgesic effect

    Time frame: 0-48 hours after titration to pain relief

    To compare the analgesic effect of the study treatments using an Investigator- and patient-administered VRS-11 scale of pain intensity over the following time periods following achievement of baseline pain relief.

    • 0-12 hours (AUCbaseline-12)
    • 0-48 hours (AUCbaseline - 48)
    • 12-24 hours (AUC12 - 24)
    • 24-48 hours (AUC24 - 48) Pain levels will be compared using the AUC from baseline.
  2. The incidence and severity of nausea

    Time frame: 0-48 hours

    To compare the incidence and severity of nausea in the study treatment groups over the following time periods following achievement of baseline pain relief: 0-12 hours, 0-24 hours, 0-48 hours, 12-24 hours, 24-48 hours.

  3. The incidence and severity of vomiting

    Time frame: 0-48 hours

    To compare the incidence and severity of vomiting in the study treatment groups over the following time periods following achievement of baseline pain relief: 0-12 hours, 0-24 hours, 0-48 hours, 12-24 hours, 24-48 hours

  4. The amounts of study drug required to achieve a baseline pain severity score of ≤ 3

    Time frame: 60-30mins before close of surgery to time 0.

    To compare the amounts of study drug required to achieve a baseline pain severity score of ≤ 3

Sponsors and collaborators

Lead sponsor

Paion UK Ltd.

Industry

Collaborators

  • Chiltern International Ltd.
  • HFL Ltd.

Registry information

Official study title

A Randomised Double-blind Study to Compare the Analgesic Efficacy and Safety Profiles of M6G and Morphine, as a Loading Dose Followed by PCA, in Patients Suffering Moderate to Severe Post-operative Pain Requiring PCA for at Least 24 Hours

Important dates

Study start
2005
Primary completion
2006
Study completion
2006
First posted
Mar 8, 2010
Registry last updated
Aug 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.